NBRV:Nabriva Therapeutics Plc - Stock Price Quote and Dividend Data
NBRV STOCK PRICE LATEST CLOSE
$1.42
EXCHANGE
NASDAQ
SECTOR / SEGMENT / INDUSTRY
Health Care / Pharmaceuticals & Biotechnology / Pharmaceuticals
Nabriva Therapeutics Plc Dividend Information
Trailing 12 Month Dividend YieldN/A
Projected 10 Year Dividend Yield0.00%
Dividend Yield 5 Year Average0.00%
Dividend Rate (IAD)$0.00
Dividend Payout Ratio0.00%
Dividend Payout Ratio 5 yr Average0.00%
Dividend Growth Rate 3 yr Average0.00%
Dividend Growth Rate 5 yr Average0.00%
Dividend AllStar™ Ranking
Consecutive Dividend Increases0 Years
Dividend Declaration DateNone
Dividend Ex DateNone
Dividend Record DateNone
Dividend Pay DateNone
Dividend Amount Current$0.000
Dividend Amount Previous$0.000
Dividends Paid in the Last 12 Months0
First Dividend PaidNone
Nabriva Therapeutics Plc Stock Price Information
52-Week Low/High Stock Price$1.22 - $8.45
Percent Held by Institutions0.06%
Revenue$47,506,000
Net Income$-79,963,000
Cash Flow$-1,625,000
EPS-7.77%
Market Cap$4,545,420
PE Ratio0
PE Ratio to Industry41%
Debt-Equity Ratio158.55%
Debt-Equity to Industry3.33%
Total Return Last 12 Months-68.34%
Total Return Last 3 Years-99.25%
Total Return Last 5 Years-99.79%
Latest Trade DateJul. 31, 2023
Nabriva Therapeutics Plc Annual Stock Dividends
No Data available for Payment History.
Nabriva Therapeutics Plc Dividend Payment History
| No dividends retrieved for NBRV |
Nabriva Therapeutics Plc Other Dividend Details
Nabriva Therapeutics is a holding company. Through its subsidiaries, Co. is a biopharmaceutical company engaged in the research, development and commercialization of anti-infective agents to treat serious infections. Co. has approval from the U.S. Food and Drug Administration for XENLETA for the treatment of adults with community-acquired bacterial pneumonia. XENLETA is an oral and intravenous treatment in the pleuromutilin class of antibiotics available for the systematic administration in humans. Co.'s CONTEPO is a potentially epoxide antibiotic for intravenous use in the U.S. for complicated urinary tract infections. Co. may develop XENLETA and CONTEPO for additional indications.
SectorHealth Care
SegmentPharmaceuticals & Biotechnology
IndustryPharmaceuticals
Dividend AllStar™ Ranking
Re-Investment AgentNone
Direct Purchase Minimum$0
Optional Cash Pay Min-Max$0 - $0
Optional Cash Payment FrequencyNone
Jun. 03, 2023NBRV STOCK PRICE DECREASE: Nabriva Therapeutics Plc on 06-03-2023 decreased stock price > 10% from $1.63 to $1.46
May. 23, 2023NBRV STOCK PRICE DECREASE: Nabriva Therapeutics Plc on 05-23-2023 decreased stock price > 10% from $1.95 to $1.65
May. 20, 2023NBRV STOCK PRICE INCREASE: Nabriva Therapeutics Plc on 05-20-2023 increased stock price > 10% from $1.66 to $1.95
May. 10, 2023NBRV STOCK PRICE INCREASE: Nabriva Therapeutics Plc on 05-10-2023 increased stock price > 10% from $1.49 to $1.67
May. 09, 2023NBRV STOCK PRICE DECREASE: Nabriva Therapeutics Plc on 05-09-2023 decreased stock price > 10% from $1.72 to $1.49
Apr. 07, 2023NBRV STOCK PRICE INCREASE: Nabriva Therapeutics Plc on 04-07-2023 increased stock price > 10% from $1.59 to $1.75
Feb. 02, 2023NBRV STOCK PRICE INCREASE: Nabriva Therapeutics Plc on 02-02-2023 increased stock price > 10% from $1.59 to $1.76
Jan. 11, 2023NBRV STOCK PRICE INCREASE: Nabriva Therapeutics Plc on 01-11-2023 increased stock price > 10% from $1.36 to $1.53
Jan. 07, 2023NBRV STOCK PRICE DECREASE: Nabriva Therapeutics Plc on 01-07-2023 decreased stock price > 10% from $2.36 to $1.30
Dec. 28, 2022NBRV STOCK PRICE 52 WEEK LOW: Nabriva Therapeutics Plc on 12-28-2022 hit a 52 week low of $1.75
Apr. 10, 2025IBO STOCK PRICE DECREASE: Impact Biomedical Inc on 04-10-2025 decreased stock price > 10% from $0.65 to $0.52
Apr. 10, 2025SXTP STOCK PRICE DECREASE: 60 Degrees Pharmaceuticals Inc on 04-10-2025 decreased stock price > 10% from $2.87 to $2.50
Apr. 10, 2025BMYMP STOCK PRICE DECREASE: $2 Cv. Pfd./Bristol Myers Squibb Co. on 04-10-2025 decreased stock price > 10% from $1,003.20 to $901.50
Apr. 10, 2025PBMWW STOCK PRICE DECREASE: Wt Exp/Psyence Biomedical Ltd on 04-10-2025 decreased stock price > 10% from $0.03 to $0.02
Apr. 10, 2025UPC STOCK PRICE DECREASE: Ord Shs (New)/Universe Pharmaceuticals Inc on 04-10-2025 decreased stock price > 10% from $3.95 to $3.28
Apr. 10, 2025SXTPW STOCK PRICE DECREASE: Wt Exp/60 Degrees Pharmaceuticals Inc on 04-10-2025 decreased stock price > 10% from $0.07 to $0.04
Apr. 10, 2025RGBP STOCK PRICE DECREASE: Regen BioPharma Inc on 04-10-2025 decreased stock price > 10% from $0.06 to $0.05
Apr. 10, 2025DRRX STOCK PRICE DECREASE: Durect Corp on 04-10-2025 decreased stock price > 10% from $0.80 to $0.71
Apr. 10, 2025IXHL STOCK PRICE DECREASE: Incannex Healthcare Inc on 04-10-2025 decreased stock price > 10% from $0.84 to $0.68
Apr. 10, 2025CLABF STOCK PRICE DECREASE: Com No Par/Core One Labs Inc on 04-10-2025 decreased stock price > 10% from $0.09 to $0.04
